Overall rank by patents
#25,759
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 10 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE).
The verdict
Akadeum holds 10 US patents across 10 technology areas, rank #25,759 of 50,000 tracked assignees.
Akadeum Life Sciences, Inc. has been granted 10 US utility patents between 2019 and 2025, placing Akadeum Life Sciences, Inc. at rank #25,759 across all assignees tracked by PlainPatent. This portfolio spans 10 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.3 claims per patent with primary concentration in B01L (CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE). As a US Corporation, Akadeum Life Sciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Akadeum sits between Aimmune Therapeutics, Inc. (10 patents, rank #25,755) and Alert Core, Inc. (10 patents, rank #25,763) - the closest US assignees by grant volume. The composite Innovation Score of 49.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 1 in the 2015–2019 window, a +800% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Akadeum Life Sciences, Inc.'s 17.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 10 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Akadeum Life Sciences, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Aimmune Therapeutics, Inc.
10 patents
Airbus Corporate Jet Centre
10 patents
Aires Medical LLC.
10 patents
Aix-Marseille Universite
10 patents
Akoya Biosciences, Inc.
10 patents
Alcatel Submarine Networks
10 patents
Alcotek, Inc.
10 patents
Alert Core, Inc.
10 patents
Akadeum Life Sciences, Inc.
10 patents
What this shows Akadeum holds 10 patents at rank #25,759, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Akadeum's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
50 Top 14% higher than 86% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 10.0% |
| 2022 | 1 | 10.0% |
| 2023 | 2 | 20.0% |
| 2024 | 4 | 40.0% |
| 2025 | 2 | 20.0% |
Top 10 of 10 technology areas
Overall rank by patents
#25,759
Across all tracked assignees
49.8 out of 100
How to use this portfolio
Akadeum's 10 grants land it in the top 14% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.